A double-blind, randomised, placebo controlled single ascending doses (SAD) and multiple ascending dose (MAD) study of MOR106 in healthy volunteers and patients with moderate to severe atopic dermatitis.

Trial Profile

A double-blind, randomised, placebo controlled single ascending doses (SAD) and multiple ascending dose (MAD) study of MOR106 in healthy volunteers and patients with moderate to severe atopic dermatitis.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs MOR 106 (Primary)
  • Indications Atopic dermatitis; Chronic obstructive pulmonary disease; Osteoarthritis; Osteoporosis; Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors Galapagos NV
  • Most Recent Events

    • 29 Jun 2017 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017.
    • 29 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
    • 29 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top